Background：Adalimumab is a recombinant human IgG1 monoclonal antibody specific for Tumor Necrosis Factor-Alpha TNF-a and is used to treat rheumatic arthritis, intestinal disorders, dermatological diseases and cancer. Adalimumab specifically binds to TNF alpha and blocks its interaction with p55 and p75 cell surface TNF receptors and reduces the inflammation and subsequently improves the patient’s health. Drug level quantification can be important to adapt patient prescription or to switch to an alternative TNF inhibitor drug.
